Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response

Sun, Nian‐Kang; Huang, Shang‐Lang; Chang, Phei‐Lang; Lu, Hsing-Pang; Chao, Chuck C.‐K.

doi:10.18632/oncotarget.2654

Cited by 31 publications

(53 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B). Furthermore, the effect of phentolamine on paclitaxel resistance was studied through modeling in vitro paclitaxel resistance in SKOV3 cells . The data demonstrated that paclitaxel was 26‐time less potent in inhibiting the proliferation of paclitaxel‐resistant SKOV3 cells (SKOV3/Tx) than that in parent SKOV3 cells (Fig.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway

Hsu

Liu

et al. 2015

Prostate

Self Cite

View full text Add to dashboard Cite

The data suggest that phentolamine is a potential anticancer agent. In contrast to a wide variety of microtubule disrupting agents, phentolamine induces microtubule assembly, leading to mitotic arrest of the cell cycle which "in turn" induces subsequent mitochondrial damage and activation of related apoptotic signaling pathways in CRPC cells. Furthermore, combination between phentolamine and paclitaxel induces a synergistic apoptotic cell death. Phentolamine has a simple chemical structure and is not a P-gp substrate. Optimization of phentolamine structure may also be a potential approach for further development.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The cells were cultured in paclitaxel‐free medium for 1 week before further studies. Episodic determinations of inhibitory concentration 50% (IC 50 ) values confirmed that paclitaxel‐resistant phenotypes were stable for at least 2 months in drug‐free medium .…”

Section: Methodsmentioning

confidence: 99%

Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway

Hsu

Liu

et al. 2015

Prostate

Self Cite

View full text Add to dashboard Cite

show abstract

“…A study analysing chemoresistance to the drug 3-bis (2-chloroethyl)-1-nitrosourea in malignant rat glioma cells found PPIA to be decreased in the drug resistant compared with responsive cells at the protein level 39 , confounding the results observed here. Interestingly a study analysing paclitaxel chemoresistance in the ovarian cancer cell line SKOV3 found another PPIase, FKBP5, to be transiently up-regulated 100 fold at the mRNA level whilst chemoresistance was being established in the cells 40 . Long term expression of FKBP5 however, was decreased in the resistant cells compared to the responsive cells.…”

Section: Discussionmentioning

confidence: 99%

Novel IEF Peptide Fractionation Method Reveals a Detailed Profile of N-Terminal Acetylation in Chemotherapy-Responsive and -Resistant Ovarian Cancer Cells

et al. 2016

View full text Add to dashboard Cite

The new agreement specifically addresses what authors can do with different versions of their manuscript -e.g. use in theses and collections, teaching and training, conference presentations, sharing with colleagues, and posting on websites and repositories. The terms under which these uses can occur are clearly identified to prevent misunderstandings that could jeopardize final publication of a manuscript (Section II, Permitted Uses by Authors). Easy Reference User Guide Posting Accepted and Published Works on Websites and Repositories:A digital file of the Accepted Work and/or the Published Work may be made publicly available on websites or repositories (e.g. the Author's personal website, preprint servers, university networks or primary employer's institutional websites, third party institutional or subject-based repositories, and conference websites that feature presentations by the Author(s) based on the Accepted and/or the Published Work) under the following conditions:• It is mandated by the Author(s)' funding agency, primary employer, or, in the case of Author(s) employed in academia, university administration.• If the mandated public availability of the Accepted Manuscript is sooner than 12 months after online publication of the Published Work, a waiver from the relevant institutional policy should be sought. If a waiver cannot be obtained, the Author(s) may sponsor the immediate availability of the final Published Work through participation in the ACS AuthorChoice program-for information about this program see http://pubs.acs.org/page/policy/authorchoice/index.html.• If the mandated public availability of the Accepted Manuscript is not sooner than 12 months after online publication of the Published Work, the Accepted Manuscript may be posted to the mandated website or repository. The following notice should be included at the time of posting, or the posting amended as appropriate: "This document is the Accepted Manuscript version of a Published Work that appeared in final form in [JournalTitle], copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles on Request authordirected link to Published Work, see http://pubs.acs.org/page/policy/articlesonrequest/index.html]." • The posting must be for non-commercial purposes and not violate the ACS' "Ethical Guidelines to Publication of Chemical Research" (see http://pubs.acs.org/ethics).• Regardless of any mandated public availability date of a digital file of the final Published Work, Author(s) may make this file available only via the ACS AuthorChoice Program. For more information, see http://pubs.acs.org/page/policy/authorchoice/index.html. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59

show abstract

“…Epidemiologic and biological data have suggested that androgens and androgen receptor (AR) may play a role in the occurrence of ovarian cancer (3,4). The AR is a ligand-dependent transcriptional factor mediating the actions of testosterone and dihydrotesterone (5).…”

Section: Introductionmentioning

confidence: 99%

“…Mapped to X chromosome (q11. [2][3][4][5][6][7][8][9][10][11][12], the AR gene includes eight exons. In exon 1 is a trinucleotide cytosine, adenine, guanine (CAG) repeat, which encodes a polyglutamine tract with varying lengths (5).…”

Section: Introductionmentioning

confidence: 99%

Androgen receptor gene CAG repeat polymorphism and ovarian cancer risk: A meta-analysis

Deng

Wang

2017

BST

View full text Add to dashboard Cite

Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response

Cited by 31 publications

References 43 publications

Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway

Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway

Novel IEF Peptide Fractionation Method Reveals a Detailed Profile of N-Terminal Acetylation in Chemotherapy-Responsive and -Resistant Ovarian Cancer Cells

Androgen receptor gene CAG repeat polymorphism and ovarian cancer risk: A meta-analysis

Contact Info

Product

Resources

About